Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $29
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $25 to $29.
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $25 to $29.